Novo Nordisk Ignites the Next Level: Triple Hormone Drug Surpasses Ozempic

Danish pharmaceutical giant Novo Nordisk is launching a new contender in the lucrative weight-loss drug market. An experimental medication developed in collaboration with the Chinese company The United Bio-Technology (Hengqin) Co. has delivered impressive results in clinical studies. The active ingredient UBT251 could herald the next generation of obesity and diabetes treatment. A $2 Billion Race Against the Kilos In a 24-week Phase 2 study involving Chinese patients with type 2 diabetes, UBT251 achieved an average weight reduction of...